Howland Capital Management LLC Cuts Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Howland Capital Management LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.2% during the first quarter, according to its most recent filing with the SEC. The fund owned 77,531 shares of the medical research company’s stock after selling 141 shares during the quarter. Thermo Fisher Scientific accounts for approximately 2.2% of Howland Capital Management LLC’s portfolio, making the stock its 11th largest holding. Howland Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $45,092,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Team Hewins LLC boosted its holdings in shares of Thermo Fisher Scientific by 0.7% in the 1st quarter. Team Hewins LLC now owns 3,171 shares of the medical research company’s stock worth $1,844,000 after buying an additional 21 shares during the last quarter. Csenge Advisory Group lifted its holdings in Thermo Fisher Scientific by 4.7% during the first quarter. Csenge Advisory Group now owns 3,546 shares of the medical research company’s stock valued at $2,061,000 after purchasing an additional 158 shares during the last quarter. Richardson Financial Services Inc. lifted its holdings in Thermo Fisher Scientific by 7.3% during the first quarter. Richardson Financial Services Inc. now owns 1,646 shares of the medical research company’s stock valued at $957,000 after purchasing an additional 112 shares during the last quarter. Signaturefd LLC lifted its holdings in Thermo Fisher Scientific by 1.7% during the first quarter. Signaturefd LLC now owns 8,347 shares of the medical research company’s stock valued at $4,851,000 after purchasing an additional 143 shares during the last quarter. Finally, FDx Advisors Inc. lifted its holdings in Thermo Fisher Scientific by 4.6% during the first quarter. FDx Advisors Inc. now owns 8,065 shares of the medical research company’s stock valued at $4,687,000 after purchasing an additional 355 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Up 1.1 %

Shares of NYSE:TMO traded up $5.67 during trading on Thursday, reaching $542.54. 1,402,436 shares of the company traded hands, compared to its average volume of 1,541,105. The firm has a market capitalization of $207.10 billion, a price-to-earnings ratio of 34.44, a P/E/G ratio of 2.50 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. The business’s fifty day moving average is $569.33 and its 200-day moving average is $563.82.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The firm had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. Thermo Fisher Scientific’s payout ratio is 10.01%.

Wall Street Analysts Forecast Growth

TMO has been the topic of several recent research reports. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective on the stock. Evercore ISI dropped their price objective on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Deutsche Bank Aktiengesellschaft upped their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. The Goldman Sachs Group upped their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $650.00 price target (up from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $606.47.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Insiders sold 22,000 shares of company stock valued at $12,532,780 over the last quarter. 0.34% of the stock is owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.